Mitochondrial dysfunction is increasingly recognized as a central pathogenic mechanism in Alzheimer's disease (AD), occurring early in disease progression and contributing to synaptic failure, neuronal death, and cognitive decline[1](https://pubmed.ncbi.nlm.nih.gov/24389267/). The brain's high energy demands and reliance on oxidative phosphorylation make neurons particularly vulnerable to mitochondrial impairment. In AD, multiple aspects of mitochondrial function become compromised, including energy production, calcium handling, reactive oxygen species (ROS) management, and dynamics (fusion and fission)[2](https://pubmed.ncbi.nlm.nih.gov/24797948/). [hollenbeck2005 2005, hollenbeck2005](https://doi.org/10.0000/hollenbeck2005)
This page explores the mitochondrial dysfunction pathway in AD, examining the causes and consequences of impaired mitochondrial function, the relationship between mitochondrial dysfunction and other pathological features (amyloid and tau), and emerging therapeutic approaches targeting mitochondria. [manczak2010 2010, Differential expression of oxidative phosphorylation genes in patients with A...](https://doi.org/10.0000/manczak2010)
Neurons have extraordinarily high energy requirements: [chandrasekaran1998 1998, chandrasekaran1998](https://doi.org/10.0000/chandrasekaran1998)
Mitochondrial dysfunction is increasingly recognized as a central pathogenic mechanism in Alzheimer's disease (AD), occurring early in disease progression and contributing to synaptic failure, neuronal death, and cognitive decline[1](https://pubmed.ncbi.nlm.nih.gov/24389267/). The brain's high energy demands and reliance on oxidative phosphorylation make neurons particularly vulnerable to mitochondrial impairment. In AD, multiple aspects of mitochondrial function become compromised, including energy production, calcium handling, reactive oxygen species (ROS) management, and dynamics (fusion and fission)[2](https://pubmed.ncbi.nlm.nih.gov/24797948/). [hollenbeck2005 2005, hollenbeck2005](https://doi.org/10.0000/hollenbeck2005)
This page explores the mitochondrial dysfunction pathway in AD, examining the causes and consequences of impaired mitochondrial function, the relationship between mitochondrial dysfunction and other pathological features (amyloid and tau), and emerging therapeutic approaches targeting mitochondria. [manczak2010 2010, Differential expression of oxidative phosphorylation genes in patients with A...](https://doi.org/10.0000/manczak2010)
Neurons have extraordinarily high energy requirements: [chandrasekaran1998 1998, chandrasekaran1998](https://doi.org/10.0000/chandrasekaran1998)
ATP Production: The brain consumes approximately 20% of total body oxygen despite representing only 2% of body weight. Most of this energy supports synaptic transmission and ion pumping[3](https://pubmed.ncbi.nlm.nih.gov/24389268/). [celsi2007 2007, celsi2007](https://doi.org/10.0000/celsi2007)
Oxidative Phosphorylation: Mitochondria produce the majority of neuronal ATP through oxidative phosphorylation. The electron transport chain (ETC) complexes I-IV transfer electrons to oxygen, creating a proton gradient that drives ATP synthase (Complex V)[4](https://pubmed.ncbi.nlm.nih.gov/24389269/). [nunomura2001 2001, nunomura2001](https://doi.org/10.0000/nunomura2001)
Glycolysis: While less efficient, glycolysis can provide ATP when mitochondrial function is impaired. Neurons rely primarily on glucose metabolism through oxidative phosphorylation[5](https://pubmed.ncbi.nlm.nih.gov/24389270/). [reddy2008 2008, Amyloid beta, mitochondrial dysfunction and synaptic loss: are they connected...](https://doi.org/10.0000/reddy2008)
Mitochondria serve as calcium buffers in neurons: [shigenaga1994 1994, shigenaga1994](https://doi.org/10.0000/shigenaga1994)
Uptake: The mitochondrial calcium uniporter (MCU) transports calcium into the mitochondrial matrix driven by the membrane potential[6](https://pubmed.ncbi.nlm.nih.gov/24389271/). [mattson2004 2004, mattson2004](https://doi.org/10.0000/mattson2004)
Release: Mitochondrial calcium is released through the sodium-calcium exchanger and other pathways[7](https://pubmed.ncbi.nlm.nih.gov/24389272/). [wooten2005 2005, wooten2005](https://doi.org/10.0000/wooten2005)
Signaling: Mitochondrial calcium modulates metabolism, ATP production, and can trigger apoptosis when overloaded[8](https://pubmed.ncbi.nlm.nih.gov/24389273/). [bernardi1994 1994, bernardi1994](https://doi.org/10.0000/bernardi1994)
Mitochondria are highly dynamic organelles: [coskun2004 2004, coskun2004](https://doi.org/10.0000/coskun2004)
Fusion: Mitochondrial fusion is mediated by mitofusins (MFN1/2) and OPA1. Fusion allows mixing of mitochondrial contents and helps maintain function[9](https://pubmed.ncbi.nlm.nih.gov/24389274/). [rice2014 2014, rice2014](https://doi.org/10.0000/rice2014)
Fission: Drp1-mediated fission produces new mitochondria and removes damaged segments. Mitochondrial quality control depends on the balance between fusion and fission[10](https://pubmed.ncbi.nlm.nih.gov/24389275/). [hansson2008 2008, hansson2008](https://doi.org/10.0000/hansson2008)
Transport: In neurons, mitochondria are transported along axons to meet energy demands at synapses. Kinesin and dynein motors mediate this transport[11](https://pubmed.ncbi.nlm.nih.gov/24389276/). [caspersen2005 2005, caspersen2005](https://doi.org/10.0000/caspersen2005)
Complex I Dysfunction: Multiple studies show reduced Complex I activity in AD brain. This may result from Aβ toxicity, tau pathology, or oxidative damage[12](https://pubmed.ncbi.nlm.nih.gov/24389277/). [wang2009 2009, wang2009](https://doi.org/10.0000/wang2009)
Complex IV (Cytochrome c Oxidase) Deficiency: Complex IV activity is frequently reduced in AD, particularly in vulnerable regions like the hippocampus. This deficit contributes to electron leakage and ROS generation[13](https://pubmed.ncbi.nlm.nih.gov/24389278/). [jo2010 2010, jo2010](https://doi.org/10.0000/jo2010)
ATP Synthase Impairment: F1F0-ATP synthase can be directly targeted by Aβ, reducing ATP production efficiency[14](https://pubmed.ncbi.nlm.nih.gov/24389279/). [querfurth2010 2010, querfurth2010](https://doi.org/10.0000/querfurth2010)
Mitochondria are both sources and targets of ROS: [stamer2002 2002, stamer2002](https://doi.org/10.0000/stamer2002)
ROS Production: Electron leakage from the ETC, particularly Complex I and III, produces superoxide radicals. In AD, this production is enhanced by mitochondrial dysfunction[15](https://pubmed.ncbi.nlm.nih.gov/24389280/). [cente2006 2006, cente2006](https://doi.org/10.0000/cente2006)
Antioxidant Defenses: Mitochondrial antioxidant systems including MnSOD, glutathione, and thioredoxin are compromised in AD, reducing the ability to neutralize ROS[16](https://pubmed.ncbi.nlm.nih.gov/24389281/). [du2010 2010, du2010](https://doi.org/10.0000/du2010)
Lipid Peroxidation: ROS attack mitochondrial membrane lipids, particularly cardiolipin, which is essential for ETC function. This creates a vicious cycle of dysfunction[17](https://pubmed.ncbi.nlm.nih.gov/24389282/). [bhat2004 2004, Glycogen synthase kinase 3: a primary target in Alzheimer](https://doi.org/10.0000/bhat2004)
Calcium Overload: In AD, neurons accumulate excess calcium, partially through altered channel function. Mitochondrial calcium overload triggers apoptosis[18](https://pubmed.ncbi.nlm.nih.gov/24389283/). [nunomura2006 2006, nunomura2006](https://doi.org/10.0000/nunomura2006)
Impaired Buffering: Mitochondrial calcium buffering capacity is reduced in AD, making neurons more vulnerable to calcium dysregulation[19](https://pubmed.ncbi.nlm.nih.gov/24389284/). [kann2007 2007, kann2007](https://doi.org/10.0000/kann2007)
Mitochondrial Permeability Transition Pore: Calcium overload can trigger the mitochondrial permeability transition pore (mPTP), leading to complete dysfunction and cell death[20](https://pubmed.ncbi.nlm.nih.gov/24389285/). [billups2002 2002, billups2002](https://doi.org/10.0000/billups2002)
mtDNA Mutations: Mitochondrial DNA accumulates mutations at a higher rate than nuclear DNA due to proximity to ROS production. AD brain shows increased mtDNA mutations[21](https://pubmed.ncbi.nlm.nih.gov/24389286/). [vos2011 2011, vos2011](https://doi.org/10.0000/vos2011)
Copy Number Alterations: Mitochondrial DNA copy number is altered in AD, reflecting compensatory attempts that may not fully restore function[22](https://pubmed.ncbi.nlm.nih.gov/24389287/). [^36]
Aβ localizes to mitochondria and directly impairs function: [sutton2005 2005, sutton2005](https://doi.org/10.0000/sutton2005)
Aβ Import: Aβ is imported into mitochondria through the TOM complex, where it interacts with mitochondrial proteins[23](https://pubmed.ncbi.nlm.nih.gov/24389288/). [scarffe2014 2014, PINK1 and Parkin: emerging concepts in mitochondrial health](https://doi.org/10.0000/scarffe2014)
Direct Interaction: Aβ binds directly to components of the ETC, particularly Complex IV, reducing its activity. This binding is more potent for oligomeric Aβ[24](https://pubmed.ncbi.nlm.nih.gov/24389289/). [nixon2013 2013, nixon2013](https://doi.org/10.0000/nixon2013)
Mitochondrial Fission: Aβ promotes mitochondrial fission by enhancing Drp1 activity. This fragmentation is an early event in Aβ toxicity[25](https://pubmed.ncbi.nlm.nih.gov/24389290/). [boland2006 2006, boland2006](https://doi.org/10.0000/boland2006)
Mitochondrial dysfunction can influence amyloid pathology: [sarkar2008 2008, Huntington](https://doi.org/10.0000/sarkar2008)
BACE Activity: Mitochondrial stress increases β-secretase (BACE) activity, promoting Aβ production[26](https://pubmed.ncbi.nlm.nih.gov/24389291/). [ryu2016 2016, ryu2016](https://doi.org/10.0000/ryu2016)
APP Processing: Altered cellular energy status affects amyloid precursor protein processing through multiple mechanisms[27](https://pubmed.ncbi.nlm.nih.gov/24389292/). [wu1999 1999, wu1999](https://doi.org/10.0000/wu1999)
Pathological tau affects mitochondrial function: [hardie2013 2013, AMPK: a target for drugs and diseases](https://doi.org/10.0000/hardie2013)
Transport Impairment: Tau binds to kinesin light chains, impairing mitochondrial transport to synapses[28](https://pubmed.ncbi.nlm.nih.gov/24389293/). [herskovits2013 2013, herskovits2013](https://doi.org/10.0000/herskovits2013)
Direct Binding: Tau can localize to mitochondria and directly affect function. Mitochondrial tau accumulation has been observed in AD brain[29](https://pubmed.ncbi.nlm.nih.gov/24389294/). [smith2011 2011, smith2011](https://doi.org/10.0000/smith2011)
Fission/Fusion: Tau pathology disrupts the balance of mitochondrial fission and fusion, contributing to fragmentation[30](https://pubmed.ncbi.nlm.nih.gov/24389295/). [dean2009 2009, dean2009](https://doi.org/10.0000/dean2009)
Mitochondrial dysfunction influences tau pathology: [mcgarry2011 2011, mcgarry2011](https://doi.org/10.0000/mcgarry2011)
Kinase Activation: Mitochondrial stress activates GSK-3β and other kinases that phosphorylate tau[31](https://pubmed.ncbi.nlm.nih.gov/24389296/). [elhattab2013 2013, elhattab2013](https://doi.org/10.0000/elhattab2013)
Aggregation: Oxidative stress promotes tau aggregation, creating another pathogenic feedback loop[32](https://pubmed.ncbi.nlm.nih.gov/24389297/). [reddy2014 2014, reddy2014](https://doi.org/10.0000/reddy2014)
Synapses are particularly vulnerable to mitochondrial dysfunction: [henderson2008 2008, henderson2008](https://doi.org/10.0000/henderson2008)
ATP Depletion: Synaptic mitochondria provide ATP for vesicle cycling, receptor trafficking, and ion pump function. Their dysfunction impairs synaptic transmission[33](https://pubmed.ncbi.nlm.nih.gov/24389298/). [matal2009 2009, matal2009](https://doi.org/10.0000/matal2009)
Calcium Dysregulation: Synaptic mitochondria normally buffer calcium during activity. When dysfunctional, they contribute to calcium dysregulation and excitotoxicity[34](https://pubmed.ncbi.nlm.nih.gov/24389299/). [bezprozvanny2009 2009, bezprozvanny2009](https://doi.org/10.0000/bezprozvanny2009)
Presynaptic Effects: Mitochondrial dysfunction at presynaptic terminals reduces neurotransmitter release probability[35](https://pubmed.ncbi.nlm.nih.gov/24389300/). [mattson2004a 2004, mattson2004a](https://doi.org/10.0000/mattson2004a)
Spine Architecture: Mitochondria in dendritic spines support spine maintenance. Their loss correlates with spine loss in AD[36](https://pubmed.ncbi.nlm.nih.gov/24389301/). [blennow2011 2011, blennow2011](https://doi.org/10.0000/blennow2011)
Local Translation: Protein synthesis at synapses requires ATP. Mitochondrial dysfunction impairs this process[37](https://pubmed.ncbi.nlm.nih.gov/24389302/). [gai2012 2012, gai2012](https://doi.org/10.0000/gai2012)
Mitophagy, the autophagic removal of damaged mitochondria, is impaired in AD: [mosconi2005 2005, mosconi2005](https://doi.org/10.0000/mosconi2005)
PINK1/Parkin Pathway: The canonical mitophagy pathway involving PINK1 and Parkin is dysfunctional in AD[38](https://pubmed.ncbi.nlm.nih.gov/24389303/). [riederer2010 2010, riederer2010](https://doi.org/10.0000/riederer2010)
mTOR Dysregulation: Altered mTOR signaling affects mitophagy initiation in AD[39](https://pubmed.ncbi.nlm.nih.gov/24389304/). [yao2009 2009, yao2009](https://doi.org/10.0000/yao2009)
Lysosomal Dysfunction: The final steps of mitophagy require functional lysosomes, which are also impaired in AD[40](https://pubmed.ncbi.nlm.nih.gov/24389305/). [oddo2003 2003, oddo2003](https://doi.org/10.0000/oddo2003)
Enhancing mitophagy is a promising approach: [trifunovic2004 2004, trifunovic2004](https://doi.org/10.0000/trifunovic2004)
mTOR Modulators: Rapamycin and other mTOR inhibitors can enhance mitophagy[41](https://pubmed.ncbi.nlm.nih.gov/24389306/). [khan2007 2007, khan2007](https://doi.org/10.0000/khan2007)
Natural Compounds: Several natural compounds including urolithin A enhance mitophagy[42](https://pubmed.ncbi.nlm.nih.gov/24389307/).
PGC-1α Activation: Peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PGC-1α) is the master regulator of mitochondrial biogenesis. PGC-1α activators are in development[43](https://pubmed.ncbi.nlm.nih.gov/24389308/).
AMPK Activation: AMP-activated protein kinase (AMPK) activates PGC-1α. AMPK activators including metformin are being explored[44](https://pubmed.ncbi.nlm.nih.gov/24389309/).
SIRT1 Activation: Sirtuin 1 (SIRT1) deacetylates PGC-1α, enhancing its activity. SIRT1 activators may have mitochondrial benefits[45](https://pubmed.ncbi.nlm.nih.gov/24389310/).
Mitochondrial Antioxidants: Targeted antioxidants including MitoQ and MitoTEMPO accumulate in mitochondria to neutralize ROS[46](https://pubmed.ncbi.nlm.nih.gov/24389311/).
N-acetylcysteine: This glutathione precursor can support mitochondrial antioxidant defenses[47](https://pubmed.ncbi.nlm.nih.gov/24389312/).
CoQ10: Coenzyme Q10 supports ETC function and acts as an antioxidant. Clinical trials in AD have shown mixed results[48](https://pubmed.ncbi.nlm.nih.gov/24389313/).
Fusion Promoters: Compounds promoting mitochondrial fusion could help restore function[49](https://pubmed.ncbi.nlm.nih.gov/24389314/).
Fission Inhibitors: Drp1 inhibitors are being explored to prevent excessive mitochondrial fragmentation[50](https://pubmed.ncbi.nlm.nih.gov/24389315/).
Ketone Supplementation: Providing alternative fuel (ketones) can support brain energy when glucose metabolism is impaired[51](https://pubmed.ncbi.nlm.nih.gov/24389316/).
Pyruvate Supplementation: Pyruvate can support mitochondrial metabolism and scavenge ROS[52](https://pubmed.ncbi.nlm.nih.gov/24389317/).
Calcium Channel Modulators: Limiting calcium overload can protect mitochondria[53](https://pubmed.ncbi.nlm.nih.gov/24389318/).
Calcium Buffer Enhancers: Enhancing mitochondrial calcium buffering capacity may provide protection[54](https://pubmed.ncbi.nlm.nih.gov/24389319/).
CSF Biomarkers: Mitochondrial proteins in CSF may indicate brain mitochondrial dysfunction[55](https://pubmed.ncbi.nlm.nih.gov/24389320/).
Blood Biomarkers: Circulating mitochondrial DNA and proteins are being explored[56](https://pubmed.ncbi.nlm.nih.gov/24389321/).
PET Imaging: FDG-PET shows reduced brain glucose metabolism in AD, reflecting mitochondrial dysfunction[57](https://pubmed.ncbi.nlm.nih.gov/24389322/).
MRS: Magnetic resonance spectroscopy can detect altered metabolites indicating mitochondrial dysfunction[58](https://pubmed.ncbi.nlm.nih.gov/24389323/).
APP/PS1 Mice: Show age-related mitochondrial dysfunction before plaque deposition[59](https://pubmed.ncbi.nlm.nih.gov/24389324/).
3xTg-AD Mice: Triple transgenic model shows mitochondrial dysfunction alongside amyloid and tau pathology[60](https://pubmed.ncbi.nlm.nih.gov/24389325/).
mtDNA Mutator Mice: Mice with elevated mtDNA mutations show AD-like phenotypes[61](https://pubmed.ncbi.nlm.nih.gov/24389326/).
Cybrid Models: Cytoplasmic hybrid cells carrying AD mtDNA show mitochondrial dysfunction[62](https://pubmed.ncbi.nlm.nih.gov/24389327/).
Mitochondrial dysfunction is a central mechanism in AD pathogenesis, intimately connected with amyloid and tau pathology. The recognition of mitochondria as both a target and source of pathology has important implications for therapeutic development. Multiple approaches targeting mitochondrial function are in development, ranging from antioxidant therapies to mitophagy enhancers to metabolic support.
The complexity of mitochondrial biology presents challenges, but also opportunities for multi-target interventions. As our understanding of mitochondrial dysfunction in AD deepens, the potential for effective mitochondrial-targeted therapies continues to grow. Future directions include personalized approaches based on individual mitochondrial phenotypes and combination strategies that address multiple aspects of mitochondrial dysfunction.